Revance Therapeutics, Inc.
RVNC
RVNC was delisted on the 5th of February, 2025.
173 hedge funds and large institutions have $209M invested in Revance Therapeutics, Inc. in 2024 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 63 increasing their positions, 42 reducing their positions, and 41 closing their positions.
103% more call options, than puts
Call options by funds: $1.57M | Put options by funds: $775K
50% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 42
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
8% less funds holding
Funds holding: 188 → 173 (-15)
34% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 41
49% less capital invested
Capital invested by funds: $411M → $209M (-$202M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.28M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$2.81M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$2.4M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$2.3M |
| 5 |
Millennium Management
New York
|
+$2.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
-$10.2M |
| 2 |
CIBC Asset Management
Toronto,
Ontario, Canada
|
-$8.56M |
| 3 |
SCM
Suvretta Capital Management
New York
|
-$5.26M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$3.86M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$3.84M |
RVNC Hedge Fund Activity: Q2 2024 in Review
173 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q2 2024, worth a combined $209M — down 49% from $411M a quarter earlier.
Sellers outnumbered buyers: 41 funds closed out of RVNC and 27 opened new positions — a net loss of 14 holders — while 42 trimmed existing stakes and 63 added.
The largest buyer was BlackRock, adding an estimated $4.28M. The largest seller was Barclays, cutting an estimated $10.2M.
- 173 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q2 2024, down from 188 in Q1 2024.
- Funds reported $209M of Revance Therapeutics, Inc. stock for Q2 2024, down 49% quarter-over-quarter.
- 27 funds opened new Revance Therapeutics, Inc. positions in Q2 2024 and 41 closed out, a net change of -14 holders.
- The largest Revance Therapeutics, Inc. buyer in Q2 2024 was BlackRock, an estimated $4.28M added.
- The largest Revance Therapeutics, Inc. seller in Q2 2024 was Barclays, an estimated $10.2M sold.
Based on aggregated 13F filings for Q2 2024.